TriangleHEALTH PROFESSIONAL · SOURCE READING
Minimal Residual Disease (MRD) and Molecular Remission
Source: Childhood Acute Promyelocytic Leukemia Treatment (PDQ®)–Health Professional Version, National Cancer Institute.
Source updated: June 14, 2024 · Captured 2026-09-09.
Selected source text with whitespace normalised. This Triangle page is not an NCI PDQ summary.
Context: Prognostic Factors Affecting Risk-Based Treatment
For APL, MRD detection at the end of induction therapy lacks prognostic significance, likely related to the delayed clearance of differentiating leukemic cells destined to eventually die.[10,11] However, it is standard practice to document molecular remission after completion of two to four cycles of consolidation therapy.
Publication references
Read the original reference and check its publication notices.
Preserved source evidence · Not medical advice